Original from: roi-nj.com

Quest Diagnostics said it completed its previously announced acquisition of Haystack Oncology.

Quest reportedly paid $300 million in cash at closing and Haystack has the potential to obtain up to an additional $150 million in performance milestones.

Haystack Oncology has developed a highly sensitive minimal-residual disease testing technology, based on circulating tumor DNA, to aid in the early detection of residual or recurring cancer and better inform therapy decisions.

Quest expects to incorporate this MRD technology into the development of new blood-based clinical lab services for solid tumor cancers available beginning in 2024.

Source: Quest Diagnostics completes acquisition of Haystack Oncology